Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.

摘要: Few treatment options are available for patients with metastatic hormone-refractory prostate cancer (HRPC) that is not responsive to or continues progress after taxane-based chemotherapy. Although single-agent carboplatin has modest activity in HRPC, chemotherapy could induce a synergistic effect when combined taxanes disease resistant We report case series of 4 consecutive treated docetaxel (60-70 mg/m2) plus (area under the curve 4/5) following progression Prostate-specific antigen levels decreased by > 50% all and were associated improvement symptoms 3 patients. Treatment was well tolerated, fatigue as most common reported side effect. Patients received 4-11 cycles and, initiation docetaxel/carboplatin chemotherapy, survival ranged from 4.5 months 12 months. In this small series, there suggestion greater than expected response who exhibit despite do respond therapy. A clinical trial evaluate been initiated.